7 completed. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
Follow Rogaratinib: new trials by email Literature Review of Rogaratinib trials Research Report on Rogaratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Combination, Rogaratinib + palbociclib + fulvestrant - Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 1 | Completed | Fundacion CRIS de Investigación para Vencer el Cáncer | 9 | 2020-11-25 | 2023-12-28 |
| Rogaratinib (BAY1163877) in Chinese Patients Rogaratinib (BAY1163877) - Neoplasms | Phase 1 | Completed | Bayer | 1 | 2019-01-07 | 2021-03-29 |
| Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors Rogaratinib (BAY1163877), Copanlisib (BAY80-6946) - Advanced or Metastatic Solid Tumor | Phase 1 | Completed | Bayer | 16 | 2018-07-25 | 2022-07-14 |
| Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma Rogaratinib (BAY1163877), Atezolizumab - Urothelial Carcinoma | Phase 1 | Completed | Bayer | 37 | 2018-05-15 | 2025-04-09 |
| Rogaratinib (BAY1163877) Human Mass Balance Study Rogaratinib (BAY1163877) - Clinical Trial, Phase I, Pharmacokinetics | Phase 1 | Completed | Bayer | 6 | 2018-04-06 | 2018-08-14 |
| Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors BAY1163877 - Neoplasms | Phase 1 | Completed | Bayer | 9 | 2015-12-15 | 2018-04-18 |
| Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID - Neoplasms | Phase 1 | Completed | Bayer | 168 | 2013-12-30 | 2021-05-06 |
Neoplasms (3) · Neoplasm Metastasis (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Transitional Cell (1) · Head and Neck Neoplasms (1)
Bayer (6) · Fundacion CRIS de Investigación para Vencer el Cáncer (1)
Spain (4) · Germany (3) · South Korea (3) · United States (3) · France (2) · Japan (2) · Singapore (2) · Austria (1) · Belgium (1) · China (1) · Italy (1) · Netherlands (1) · Switzerland (1)
Luis Manso, MD (1)
PMID 30807645, PMID 31405822, PMID 39298147
2017 (2), 2018 (1)